Wednesday, June 24, 2026 | 11:47 AM ISTहिंदी में पढें
OneSource Specialty Pharma Ltd News
Onesource Specialty Pharma up 5% in weak market; rallies 21% in one week
The company will continue to derive strength from the existence of experienced promoters and positive outlook for the GLP1 segment, which is expected to yield revenue to the company from FY27 onwards.
 "Onesource Specialty Pharma up 5% in weak market; rallies 21% in one week")
Updated On : 24 Apr 2026 | 2:10 PM IST
Onesource Specialty Pharma tanks 18% on weak Q3; what should investors do?
In Q3, the company's net loss widened to ₹88.7 crore, as compared to ₹68.8 crore, year-on-year (Y-o-Y). Its revenue from operations stood at ₹290.3 crore, down 26 per cent Y-o-Y
 "Onesource Specialty Pharma tanks 18% on weak Q3; what should investors do?")
Updated On : 27 Jan 2026 | 11:46 AM IST